An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 Years) of Age With Epilepsy
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 07 Jun 2017 Biomarkers information updated
- 30 May 2017 Planned End Date changed from 1 May 2019 to 1 Mar 2019.
- 30 May 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Jun 2018.